干扰素α1b注射液雾化吸入治疗小儿病毒性肺炎的剂量效应研究

Dose-effect study of aerosol inhalation of recombinant human interferon alpha 1b injection in the treatment of viral pneumonia in children

目的:探讨重组人干扰素α1b(IFNα1b)注射液雾化吸入治疗小儿病毒性肺炎的疗效及给药剂量效应。方法:选取本院2017年3月-2019年3月儿科收治的84例病毒性肺炎患儿,采用随机数表法分为对照组(n=30)和观察组(n=54),对照组给予常规对症治疗,观察组在常规对症治疗基础上给予IFNα1b(运德素)治疗。将观察组随机分成观察A组(n=27)和观察B组(n=27)两个亚组,给药剂量分别为1.0μg·kg^-1和2.0μg·kg^-1,bid,均持续治疗7 d。观察不同组间患儿症状体征缓解时间、住院时间、临床疗效和不良反应情况。结果:观察组发热消失时间(2.03±0.97)d、咳嗽消失时间(5.48±1.07)d、肺部湿啰音消失时间(5.50±1.27)d及住院时间(6.52±1.25)d均短于对照组(2.78±1.05)d、(6.29±1.18)d、(6.57±1.35)d、(7.36±1.37)d,差异有统计学意义(P均<0.05),临床总有效率94.44%高于对照组73.33%,差异有统计学意义(P<0.05),组间不良反应率比较,差异无统计学意义(P>0.05)。观察A、B组间比较,症状体征消失时间、住院时间差异无统计学意义(P均>0.05),临床总有效率和不良反应率差异亦无统计学意义(P均>0.05)。结论:IFNα1b能有效缩短病毒性肺炎患儿症状体征消失时间和住院时间,临床疗效和安全性均较好,但临床疗效并不存在IFNα1b剂量效应,不同剂量IFNα1b的疗效接近。

Objective:To investigate the efficacy and dosage effect of aerosol inhalation of recombinant human interferon alpha 1b(IFN alpha 1b)injection in the treatment of viral pneumonia in children.Methods:A total of 84 children with viral pneumonia admitted to our hospital from March 2017 to March 2019 were randomly divided into control group(n=30)and observation group(n=54).The control group was given routine symptomatic treatment,while the observation group was given IFN alpha1B(Lutein)treatment on the basis of routine symptomatic treatment.The observation group was randomly divided into two subgroups:observation group A(n=27)and observation group B(n=27).The dosage of Bid was 1.0μg·kg^-1 and 2.0μg·kg^-1,respectively,for 7 days.The remission time of symptoms and signs,hospitalization time,clinical efficacy and adverse reactions were observed among different groups.Results:The disappearance time of fever,cough,lung moist rale and hospitalization in the observation group were shorter than those in the control group(2.78±1.05)d,(6.29±1.18)d,(6.57±1.35)d,(7.36±1.37)d,and the difference was statistically significant(P<0.05).The total clinical effective rate was 94.44%higher than 73.33%of the control group.The difference was statistically significant(P<0.05).There was no significant difference in the rate of adverse reactions between groups(P>0.05).There was no significant difference in the rate of adverse reactions between groups(P>0.05).There was no significant difference in the total effective rate and adverse reaction rate(P>0.05).Conclusions:IFN alpha 1b can effectively shorten the disappearance time of symptoms and signs and hospitalization time of children with viral pneumonia.The clinical efficacy and safety are good,but there is no dose effect of IFN alpha 1b in the clinical efficacy.The efficacy of different doses of IFN alpha 1b is similar.